Atypical Antipsychotics: Life-Cycle Management and Future TrendsDecision ResourcesDecember 11, 2006 17 Pages - SKU: DECR1398292 |
|
The $15 billion antipsychotics market will be hard hit by generics of nearly all the most frequently prescribed atypicals and by a dearth of breakthrough therapies in the pipeline. Overall market decline will be signifi cant by 2015, but current market leaders are staking out new territories to defend their franchises. Get the Answers You Need to Shape Your Strategy At present, because all marketed atypicals (except clozapine) are expensive, cost is not generally a factor in a physician's choice of agent. That will change when the patent for branded risperidone expires. What factors do physicians consider in prescribing? How will prescribing change when lower-cost generics are available? How will payers respond to availability of generic risperidone? Pending genericization and a less than robust pipeline threaten the historic growth of the antipsychotics marketplace. What kind of sales are antipsychotics likely to generate in 2010? In 2015? What is the outlook for emerging atypicals? A variety of tactics are available to manufacturers of current and emerging atypicals. What specifi c strategies are companies pursuing? Will today's prominent players continue to lead the marketplace? Scope The current market: Key players, atypical antipsychotics, current market leaders, indications, sales, major markets. Market outlook: Sales trends through 2015, key players, "new-generation" atypicals, genericization, reimbursement issues, declining markets. Survival strategies: Life-cycle management, line extensions, new indications and patient populations. Please note, the PDF e-mail from publisher version of this report is for a global site license. |
Additional Information
Mentioned in This Report—Companies
Astellas
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Johnson & Johnson
Lundbeck
Novartis
Organon
Otsuka
Pfizer
Solvay
Wyeth
Related Markets
- Life Sciences
- Pharmaceuticals
- Pharmaceuticals
- Prescription Drugs
- Therapeutic Area
- CNS/Neurology
- Behavioral Health
Behavioral Health Reports
- Key Companies: Depression - Leading players must adapt to remain competitive
- CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry players
- Product Profiles: Depression - Next generation vies for second-line patients
- Alcohol Addiction Global Clinical Trials Review, Q2, 2011
- Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns
